Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,868 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Growth Hormone Deficiency
Interventions: Macimorelin, Arginine, Clonidine; Drug · Diagnostic Test
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more

Conditions: Parkinson Disease
Interventions: Fasting, No Intervention; Other
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Type 2
Interventions: Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Cortical Dysplasia
Interventions: Classical ketogenic diet; Dietary Supplement
Lead sponsor: University College, London; Other
Eligibility: 3 Years to 15 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ARDS, Sepsis, Pneumonia
Interventions: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan; Other · Procedure · Radiation
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Patent Ductus Arteriosus
Interventions: feeding, fasting; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 23 Weeks to 33 Weeks
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 14
States / cities: San Francisco, California • San Jose, California • Chicago, Illinois + 11 more

Conditions: Development of Non-invasive Protocol
Interventions: ethanol dilution; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Dexmethylphenidate; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections, Electronic Health Record, Primary Health Care
Interventions: EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteer
Interventions: GDC-0310, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Solid Tumor
Interventions: IPN60090, pembrolizumab, paclitaxel, IPN60090 single administration; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Antioxidant Status
Interventions: Active dermal patch, Placebo dermal patch; Other
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Congenital Hyperinsulinism
Interventions: Exendin-(9-39), placebo; Drug
Lead sponsor: Diva De Leon; Other
Eligibility: 6 Months to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Subdural Hematoma
Interventions: Dextrose 5% W/ Sodium Chloride 0.225%; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Insulin Resistance, Diabetes
Interventions: Quantose IR and Quantose IGT analysis, HOMA IR the standard testing for insulin resistance; Diagnostic Test
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Healthy Volunteers
Interventions: ASP1617, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: TRE plus SOC, SOC, TRE; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: SARS CoV 2 Infection
Interventions: Testing for SARS CoV2 Antigen; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Vascular Access Complication
Interventions: AccuCath IV Catheter Device, Conventional IV Catheter Device; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Kidney Diseases
Interventions: Bardoxolone methyl oral capsule, Placebo oral capsule; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 12
States / cities: La Mesa, California • Arvada, Colorado • Denver, Colorado + 9 more

Conditions: Fibromyalgia
Interventions: Prolonged Nightly Fasting, Health Education Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cancer
Interventions: Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Detroit, Michigan

Conditions: Diabetes Mellitus, Type 2
Interventions: Telephonic intervention to prevent Diabetes Mellitus, Type 2; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 40 Years to 74 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Psoriasis, Psoriatic Arthritis
Interventions: Intermittent Fasting Diet; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

Dance and Energy Expenditure Among Adults With Parkinson's

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy

The APS Phenotyping Study

Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants

Fluid Volume During Fluid Shifts

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Rapid Effects of a Biofield Patch on Antioxidant Status and Cellular Energy

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence

Validation of a Novel Screening Test for Maternal Insulin Resistance

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

Rutgers Pilot for PREDICT- Patient POC Test

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

Prolonged Nightly Fasting in Fibromyalgia

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

Call-2-Health: Preventing Type II Diabetes

Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis